Medicare AdvantagePrior AuthMedium impact
Vanflyta® (quizartinib) (Revised)
Humana·Hematology, Oncology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
New prior authorization requirements for Vanflyta (quizartinib) for Medicare Advantage patients with newly diagnosed FLT3-positive acute myeloid leukemia. Coverage requires documented FLT3 ITD-positive disease and specific combination therapy or maintenance monotherapy protocols.
Action Required
Before January 1, 2026: Providers treating AML patients must obtain prior authorization for Vanflyta (quizartinib) prescriptions for Medicare Advantage members. Ensure documentation includes: newly diagnosed AML diagnosis, FLT3 ITD-positive test results from FDA-approved test, and treatment plan showing combination with standard chemotherapy or maintenance monotherapy following consolidation. Claims will be denied without proper prior authorization.